文献速递基础与转化研究新药、器械与细胞基因治疗研发

IgG切割内肽酶在抗AAV中和抗体存在下实现体内基因治疗

IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies.
PubMed 文献 · Nat Med · 2020-06-01

抗AAV中和抗体普遍存在并阻碍肝脏转导和载体再给药,是体内基因治疗的主要限制。研究显示IdeS内肽酶可在体外切割人IgG,在小鼠和非人灵长类中降低抗AAV抗体并增强肝脏转导,且再给药时仍有效。IdeS还降低人血浆样本中的抗AAV抗体水平。

要点

  • IdeS可切割循环IgG,降低抗AAV中和抗体水平。
  • 小鼠和非人灵长类中IdeS预处理增强AAV肝脏转导。
  • IdeS在载体再给药场景下仍提升肝脏转导。

核心结论

  • IdeS内肽酶可消除抗AAV抗体,为克服AAV基因治疗预存抗体提供潜在方案。

研究设计与样本

  • 体外实验结合小鼠被动免疫模型和非人灵长类动物研究,并检测人血浆样本。

主要发现

  • 体外IdeS处理可高效切割混合人IgG。
  • 静脉Ig被动免疫小鼠中,IdeS给药降低抗AAV抗体并实现高效肝脏基因转移。
  • 非人灵长类中AAV输注前IdeS治疗安全,增强肝脏转导,再给药时仍有效。
  • IdeS在体外降低人血浆样本(含前瞻性基因治疗试验参与者血浆)的抗AAV抗体水平。

临床怎么用

  • AAV基因治疗前可考虑用IdeS清除预存抗AAV抗体以增强肝脏转导。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Neutralizing antibodies to adeno-associated virus (AAV) vectors are highly prevalent in humans1,2, and block liver transduction3-5 and vector readministration6; thus, they represent a major limitation to in vivo gene therapy. Strategies aimed at overcoming anti-AAV antibodies are being studied7, which often involve immunosuppression and are not efficient in removing pre-existing antibodies. Imlifidase (IdeS) is an endopeptidase able to degrade circulating IgG that is currently being tested in transplant patients8. Here, we studied if IdeS could eliminate anti-AAV antibodies in the context of gene therapy. We showed efficient cleavage of pooled human IgG (intravenous Ig) in vitro upon endopeptidase treatment. In mice passively immunized with intravenous Ig, IdeS administration decreased anti-AAV antibodies and enabled efficient liver gene transfer. The approach was scaled up to nonhuman primates, a natural host for wild-type AAV. IdeS treatment before AAV vector infusion was safe and resulted in enhanced liver transduction, even in the setting of vector readministration. Finally, IdeS reduced anti-AAV antibody levels from human plasma samples in vitro, including plasma from prospective gene therapy trial participants. These results provide a potential solution to overcome pre-existing antibodies to AAV-based gene therapy.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Leborgne C, Barbon E, Alexander JM, et al. IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies. Nat Med. 2020. PMID: 32483358. doi:10.1038/s41591-020-0911-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。